flaking disease Psoriasis
Conditions
Interventions
None listed
Sponsors
TNO
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Psoriasis patients: Adults (m/f) with a mild form of psoriasis vulgaris (PASI score of maximal 12). Patients are allowed to use local corticosteroids or ointments to prevent dry skin (Appendix 2).
Exclusion criteria
Exclusion criteria: These patients have not received light therapy or another form of systemic treatments (methotrexate, cyclosporin A, anti-TNF treatments). Gender or age of the adults are not exclusion criteria (Appendix 2)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect on the psoriatic process is tested by histology and immuno-histochemical techniques in the transplanted biopsies. Main read-out is epidermal thickness. | — |
Secondary
| Measure | Time frame |
|---|---|
| RNA will be isolated from the biopsies and analyzed on important gene transcripts that appear to play a role in the development of psoriasis. Secretion of inflammatory mediators by cells from patients. Markers on cultured cells from psoriasis patients. Additionally, effects of the compounds will be evaluated on the immune cells derived from blood of the patients (in vitro) , this in parallel to the in vivo mouse study. Possibly also inflammatory cells in the skin tissue will be evaluated | — |
Countries
Netherlands
Outcome results
None listed